C1159372||Targeting
C0289507||Nrf2
C1149161||Amyloid-Beta Liaison
C0002395||Alzheimer's Disease
C0002716||Amyloid
C0002395||Alzheimer's disease
C0002395||Alzheimer's disease
C0205132||linear
C0078939||amyloid-β peptide
C0078939||amyloid-β peptide
C0242656||progression
C1510880||amyloid-β peptide
C1518762||Nrf2 pathways
C0078939||amyloid-β peptide
C0012634||disease
C0085826||antiaggregating agents
C0162493||activate transcription
C0003402||antioxidant
C0683154||responses
C1254351||lead 1
C0556043||requirements
C0078939||amyloid-β peptide
C1254351||catechol derivative 12
C1254351||12
C0079381||free radical scavenger
C1518762||Nrf2 pathway
C0017391||induce
C0289507||Nrf2
C2164680||defensive
C0919428||gene NQO1
C0040649||transcriptional response
C1254351||oligomeric intermediates
C0013221||less toxic
C1254351||prototype 1
C1523114||regulate Nrf2
C0078939||amyloid-β peptide
C1148560||activities
C1704259||pathways
C1254351||compound 12
C1254351||derivatives
C0289507||Nrf2
C0078939||amyloid-β peptide
C0007634||cellular
C1254351||drug leads
C0002395||Alzheimer's disease